Neuropeptide Y (13-36), amide, human

Research use only, not for human use.

Neuropeptide Y (13-36), amide, human is a neuropeptide Y receptor agonist.

Neuropeptide Y (13-36), amide, human is a neuropeptide Y receptor agonist.(In Vivo):Intraventricular injections of the Y2 neuropeptide Y receptor agonist porcine Neuropeptide Y (13-36) (25-3000 pM) produces a dose-dependent increase (up to 14%; ED50=0.3 nM for overall effects and 0.97 nM for the peak effects) in mean arterial blood pressure in the awake, unrestrains male rat without affecting heart rate. Central administration of porcine Neuropeptide Y (13-36) produces marked vasodepressor and bradycardic actions in the anaesthetized α-chloralose and in the awake unrestrained male rat.

——

Neuropeptide Y (13-36) (intraventricular injection; 25-3000 pmol)produces a dose-dependent increase (up to 14%; ED50 value of 0.3 nmol for overall effects and 0.97 nmol for the peak effects) in mean arterial blood pressure in the awake, unrestrained male rat without affecting heart rate. Central administration of porcine Neuropeptide Y (13-36) produces marked vasodepressor and bradycardic actions in the anaesthetized α-chloralose and in the awake unrestrained male rat.Neuropeptide Y (13-36) (intracerebroventricular injection; 50 ng; alone; injected 30 and 15 min before measurements) injected into na?ve mice impairs social novelty preference, but not sociability, and this effect is inhibited by the NPY Y2 receptor antagonist BIIE 0246. Animal Model:Male ICR mice (age 4-7 weeks)Dosage:50 ng/mouse Administration:Intracerebroventricular injectionResult:Significantly decreased interaction time with the new stranger mouse in session 3 that NPY 13-36.

Neuropeptide Y (13-36), human

Others

Other Targets

Neuropeptide Y receptor

——

——

122341-40-6

3000.4

C134H207N41O36S

>98% (HPLC)

——

——

Sequence:Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2

(-20℃)

With Ice Pack

≥ 2 years